<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with an implanted cardioverter defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> leading to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies have poor clinical outcomes and quality of life </plain></SENT>
<SENT sid="1" pm="."><plain>Antiarrhythmic agents and catheter ablation are needed to control these <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="4681">Dofetilide</z:chebi> has only been approved for the treatment of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The role of <z:chebi fb="0" ids="4681">dofetilide</z:chebi> in the control of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> has not been established </plain></SENT>
<SENT sid="4" pm="."><plain>OBJECTIVE: Evaluate the safety and efficacy of <z:chebi fb="0" ids="4681">dofetilide</z:chebi> in a consecutive group of patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> and recurrent <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) and/ or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) after other antiarrhythmic drugs have failed to suppress these <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: We studied 30 patients (age 59 ± 11; 5 women) with symptomatic VT or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> for secondary prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>These patients had an average of 1.8 ± 4.5 episodes of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> per month despite antiarrhymic therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-one patients (70%) had recurrent appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies prior to initiation of <z:chebi fb="0" ids="4681">dofetilide</z:chebi>, and 9 (30%) VTs below the programmed detection rate of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-three patients (77%) had <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Mean ejection fraction was 30 ± 14% and 26/30 (87%) had <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had previously failed 2 ± 1 antiarrhythmic drugs including <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (n = 19) and sotalol (n = 10) </plain></SENT>
<SENT sid="11" pm="."><plain>RESULTS: During the first month of treatment, 25 patients (83%) had complete suppression of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and of the 21 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies 16 (76%) had no therapies during the first month of treatment </plain></SENT>
<SENT sid="12" pm="."><plain>During a follow-up period of 32 ± 32 months, <z:chebi fb="0" ids="4681">dofetilide</z:chebi> reduced the monthly episodes of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> from 1.8 ± 4.5 to 1.0 ± 3.5 (P = 0.006) </plain></SENT>
<SENT sid="13" pm="."><plain>Monthly <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies decreased from 0.9 ± 1.4 to 0.4 ± 1.7 (P = 0.037) </plain></SENT>
<SENT sid="14" pm="."><plain>In 9 patients that presented with slow VTs under the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> detection zone, <z:chebi fb="0" ids="4681">dofetilide</z:chebi> reduced monthly VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes from 0.7 ± 0.6 to 0.1 ± 0.1 (P = 0.01) and 6 (67%) had no further <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies </plain></SENT>
<SENT sid="15" pm="."><plain><z:chebi fb="0" ids="4681">Dofetilide</z:chebi> was discontinued in 13 patients (43%) after 24 ± 30 months due to failure to control VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (n = 7), placement of a left ventricular assist device (n = 3), catheter ablation (n = 1), heart transplantation (n = 1), and left ventricular restoration surgery (n = 1) </plain></SENT>
<SENT sid="16" pm="."><plain>There were 7 documented <z:hpo ids='HP_0011420'>deaths</z:hpo> (2 patients died suddenly; 3 patients of progressive <z:hpo ids='HP_0001635'>heart failure</z:hpo>; and 2 of non-cardiac causes) </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSIONS: In patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, <z:chebi fb="0" ids="4681">dofetilide</z:chebi> decreases the frequency of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies even when other antiarrhythmic agents, including <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, have previously been ineffective </plain></SENT>
<SENT sid="18" pm="."><plain>Recurrences still occur in some patients requiring catheter ablation, mechanical support, or heart transplantation </plain></SENT>
</text></document>